Literature DB >> 23417869

Clinical characteristics and prognostic factors of adenoid cystic carcinoma of the head and neck.

Yunsuk Choi1, Sung-Bae Kim, Dok Hyun Yoon, Ji Youn Kim, Sang-wook Lee, Kyung-Ja Cho.   

Abstract

OBJECTIVES/HYPOTHESIS: This study was intended to evaluate prognostic factors and the role of postoperative radiotherapy (RT) in patients with adenoid cystic carcinoma (ACC) of the head and neck (ACCHN). STUDY
DESIGN: Retrospective study.
METHODS: Eighty-eight patients with ACCHN who underwent curative intent surgery with or without RT between 1991 and 2009 at a single institute were retrospectively analyzed.
RESULTS: Patients with ACC of the sinonasal area (P=.005) and those with diabetes mellitus (DM; P=.027) showed a significantly higher risk of local recurrence. Age (<40 or >60 years, P=.028) and tumor stage III or IV (P=.022) were significant adverse factors predicting distant metastasis. High-grade histology (P=.014) and DM (P=.027) were independently associated with shorter disease-free survival (DFS). In addition, postoperative RT (≥59 Gy) significantly enhanced local control (P=.025) and DFS (P=.001) in both univariate and multivariate analyses.
CONCLUSIONS: Age, DM, tumor site, histologic grade, and stage were independently significant prognostic factors for ACCHN. In addition, an adequate dose of postoperative radiotherapy can improve local control and DFS of patients with ACCHN.
Copyright © 2013 The American Laryngological, Rhinological and Otological Society, Inc.

Entities:  

Mesh:

Year:  2013        PMID: 23417869     DOI: 10.1002/lary.23976

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  9 in total

1.  Pattern of recurrent disease in major salivary gland adenocystic carcinoma.

Authors:  Karoliina Hirvonen; Leif Bäck; Kauko Saarilahti; Ilmo Leivo; Jaana Hagström; Antti A Mäkitie
Journal:  Virchows Arch       Date:  2015-04-03       Impact factor: 4.064

2.  Adenoid cystic carcinoma of head and neck: clinical predictors of outcome from a Canadian centre.

Authors:  J J Ko; J E Siever; D Hao; R Simpson; H Y Lau
Journal:  Curr Oncol       Date:  2016-02-18       Impact factor: 3.677

3.  Clinical Outcomes and Prognostic Factors of Adenoid Cystic Carcinoma of the Head and Neck.

Authors:  Samuel Jang; Priyesh N Patel; Randall J Kimple; Timothy M McCulloch
Journal:  Anticancer Res       Date:  2017-06       Impact factor: 2.480

Review 4.  Cervical lymph node metastasis in adenoid cystic carcinoma of the sinonasal tract, nasopharynx, lacrimal glands and external auditory canal: a collective international review.

Authors: 
Journal:  J Laryngol Otol       Date:  2016-11-14       Impact factor: 1.469

5.  A potential protective effect of metformin in adenoid cystic carcinoma.

Authors:  Peter J Lancione; Bhavna Kumar; Songzhu Zhao; Edmund A Mroz; Guy Brock; James W Rocco; Ricardo L Carrau; Amit Agrawal; Nolan Seim; Stephen Y Kang; Enver Ozer; Matthew O Old
Journal:  Oral Oncol       Date:  2020-05-07       Impact factor: 5.972

6.  Outcome of Adenoid Cystic Carcinoma of Head and Neck After Postoperative Intensity Modulation Radiotherapy: A Single Institution Study.

Authors:  Peng Xu; Shuo Wang; Yukun Luo; Jun Yin; Yazid Belkacemi; Shun Lu; Mei Feng; Jinyi Lang
Journal:  Cancer Manag Res       Date:  2021-03-15       Impact factor: 3.989

7.  Analysis of postoperative radiotherapy for non-metastatic head and neck adenoid cystic carcinoma based on SEER data.

Authors:  Yan Du; Yong Zeng
Journal:  J Int Med Res       Date:  2022-08       Impact factor: 1.573

8.  Laryngeal adenoid cystic carcinoma: Three cases reports.

Authors:  Yu Cui; Lirong Bi; Le Sun; Xin Wang; Zhanpeng Zhu
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.889

Review 9.  Radiation Therapy for Adenoid Cystic Carcinoma of the Head and Neck.

Authors:  Carlos A Rodriguez-Russo; Jacqueline C Junn; Sue S Yom; Richard L Bakst
Journal:  Cancers (Basel)       Date:  2021-12-17       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.